Anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Short stature as a result of chondrodysplasia. Growth plate abnormalities Developmental delays, specifically in language and walking. Difficulty with social interaction. A variety of mild dysmorphic features, with all patients having a prominent nose, thin upper lip, and a wide mouth. Many patients also have ptosis and wide set eyes. ADHD-like symptoms, such as inattentiveness, hyperactivity, and forgetfulness. Difficulty walking, whether from skeletal issues or neurological issues. Many patients have been observed as having mild intellectual disability, microcephaly, hypotonia, and autism. Patients may also have other neurological symptoms such as tremors, unsteady gait, poor reflexes, and seizures. A couple of patients had elevated levels of creatine kinase during infancy that later went down to normal. It's suspected there may be an increased risk of cancer, genitourinary issues, and cardiac issues, but, due to the apparent rareness of VERBAS, it's unclear if there is any connection to VERBAS.
In 2021, the average annual salary in the private sector was €18,630 for women and €24,640 for men, reflecting a 24.4% gap. This difference is partially attributed to variations in working hours, job types, and the prevalence of part-time work, which accounted for approximately 40% of the wage gap in 2017. When adjusted to full-time equivalents, the average wage gap was 15.5% in 2021, down from 17.5% in 2016. The wage gap tends to increase with age: it was 4.6% at age 25 and rose to 27.5% among those over 60. Differences in working time decrease with age, from 20% under age 25 to 10% between ages 25 and 60. For workers, women earned 14.3% less than men for equivalent hours and worked 23.3% fewer hours. Among employees, women earned 4.7% less for similar hours and had nearly equal working time. The pay gap for equal hours was 16.1% among executives and 12.2% among intermediate professions, with women in these groups also working fewer hours (4.7% and 10.9%, respectively). For equivalent positions and working hours, the wage gap was 4.3%, though occupational segregation—such as differences in sector and employer—affects this figure. In the public sector, the overall gender wage gap was 14%. Among executives, the gap was 23%; among workers, 17%; and among employees, 7%. For full-time salaried positions, the gender wage gap declined from 29.4% in 1976 to 16.3% in 2017. The gap narrowed steadily until 1980, remained largely stable until 2000, and began to decrease again thereafter, though part-time employment among women influenced this trend.
An AI agent is an artificial intelligence program that can pursue goals, use software or other tools, and take actions with some level of autonomy. Agentic AI contrasts with tool-like AI use for narrow, specific tasks such as answering questions - as with chatbots in the non-agentic forms that were common in 2023, or with traditional machine learning algorithms. While there is no universally agreed-upon definition of an AI agent, common attributes of AI agents include goal-directed behavior, use of external tools, the ability to interact with and modify an external environment, and the ability to autonomously perform multi-step tasks. Their control flow is frequently driven by large language models (LLMs). Agent systems may also include memory components, planning logic, tool interfaces, and orchestration software for coordinating agent components.
Sources: en.wikipedia.org
== Research == Oxyntomodulin could be a potential candidate for treating obesity because of its ability to suppress appetite. In a 4 week study, healthy overweight and obese volunteers were given either saline or oxyntomodulin injections. Their body weight, energy intake, and the levels of adipose hormones were taken prior to the treatment. The volunteers maintained their usual diets and daily activities and self-administered the injections three times daily, 30 minutes before their meals. In the course of 4 weeks, volunteers treated with oxyntomodulin injections had an average weight loss of 2.3±0.4 kg compared to those treated with saline who had an average of 0.5±0.5 kg, indicating oxyntomodulin was successful in weight loss.
The 22nd Brigade was deployed as a flank guard, sweeping down the Tanlwe Chaung before hooking around to the Taungup Chaung and ultimately the road to Prome; this move was intended to cut Japanese units to the north off from the Irrawaddy Delta to the south, where most of the key battles were being fought. 1RAR patrolled the area during March and April 1945 and was involved in several contacts. On 20 April it assembled at a point overlooking Tanlwe Chaung, where it was shelled by Japanese artillery and mortars dug in atop two high features to the south. On the morning of 26 April, after a few days of patrols, 1RAR took the lead in what became the Battle of Tanlwe Chaung; after about half an hour of bombing, strafing and artillery bombardment of the Japanese positions, elements of A and D Companies, 1RAR charged up the slopes and routed much of the Japanese garrison before taking both hills. Seven RAR men were killed in the action and 22 were wounded, mostly from D Company; an officer was also injured. An officer of the RAR recalled the battles of April 1945 around Taungup and Tanlwe Chaung as extremely intense:
Fibromyalgia (FM) is a long-term condition characterised by widespread chronic pain. Other symptoms can include fatigue, trouble thinking or remembering, waking up tired (unrefreshed), pain or cramps in the lower abdomen, depression, or headache. The causes of fibromyalgia are unknown, with several pathophysiologies proposed. Fibromyalgia is estimated to affect 2 to 4% of the population. Women are affected at a higher rate than men. Rates appear similar across areas of the world and among varied cultures. Fibromyalgia was first recognised in the 1950s, and defined in 1990, with updated criteria in 2011, 2016, and 2019. The treatment of fibromyalgia is symptomatic and multidisciplinary. Aerobic and strengthening exercise is recommended. Duloxetine, milnacipran, and pregabalin can give short-term pain relief to some people with FM. Symptoms of fibromyalgia persist long-term in most patients. Fibromyalgia is associated with a significant economic and social burden, and it can cause substantial functional impairment among people with the condition. People with fibromyalgia can be subjected to significant stigma and doubt about the legitimacy of their symptoms, including in the healthcare system. FM is associated with relatively high suicide rates.
Lime can be manufactured in countercurrent furnaces allowing the heat to reach high temperatures using low cost, low temperature burning fuel. Historically this was developed by the Japanese in certain types of the Anagama kiln. The kiln is built in stages, where fresh air coming to the fuel is passed downwards while the smoke and heat is pushed up and out. The heat does not leave the kiln, but is transferred back to the incoming air, and thus slowly builds up to 3,000 °C (5,430 °F) and more.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.